Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Eide, Christopher A., Zabriskie, Matthew S., Savage Stevens, Samantha L., Antelope, Orlando, Vellore, Nadeem A., Than, Hein, Schultz, Anna Reister, Clair, Phillip, Bowler, Amber D., Pomicter, AnthonyLanguage:
english
Journal:
Cancer Cell
DOI:
10.1016/j.ccell.2019.08.004
Date:
September, 2019
File:
PDF, 3.57 MB
english, 2019